<DOC>
	<DOC>NCT00154362</DOC>
	<brief_summary>Conduct disorder is a group of psychiatric symptoms that can include clinical characteristics of impulsivity and aggressive behavior. This study will investigate the efficacy a safety of oxcarbazepine in the treatment of adolescents with conduct disorder.</brief_summary>
	<brief_title>The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Adolescents With Impulsivity and Aggressive Behavior in Conduct Disorder This Study is Not Being Conducted in the United States.</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Impulsive Behavior</mesh_term>
	<mesh_term>Conduct Disorder</mesh_term>
	<mesh_term>Aggression</mesh_term>
	<mesh_term>Oxcarbazepine</mesh_term>
	<mesh_term>Carbamazepine</mesh_term>
	<criteria>History of conduct disorder, oppositional defiant disorder, and disruptive behavior disorder not otherwise specified Score &gt;8 on the Impulsivity Rating Scale Other serious medical or psychiatric conditions excluding conduct disorder, oppositional defiant disorder, and disruptive behavior disorder not otherwise specified Treatment with antiepileptic medications Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Oxcarbazepine, conduct disorder, adolescents</keyword>
</DOC>